Future perspective for the application of predictive biomarkertesting in advanced stage non-small cell lung cance

• Type: Article in International Scientific Journal
• Date: 2024

Authors

de Jager, VD (Author) Other; Timens, W (Author) Other; Bayle, A (Author) Other; Botling, J (Author) Other; Brcic, L (Author) Other; Buettner, R (Author) Other; Fernandes, MGO (Author) FMUP; Havel, L (Author) Other; Hochmair, M (Author) Other; Hofman, P (Author) Other; Janssens, A (Author) Other; van Kempe, L (Author) Other; Kern, I (Author) Other; Machado JC (Author) FMUP; Mohorcic, K (Author) Other; Popat, S (Author) Other; Ryska, A (Author) Other; Wolf, J (Author) Other; Schuuring, E (Author) Other; van der Wekken, AJ (Author) Other

Journal

The Journal is awaiting validation by the Administrative Services.

Title: LANCET REGIONAL HEALTH-EUROPE

Vol. 38

ISSN: 2666-7762

Indexing

ISI Web of Knowledge - 4 Citations

Scopus - 1 Citation

Other information

Authenticus ID: P-010-24A

DOI: 10.1016/j.lanepe.2024.100839

Abstract (EN): For patients with advanced stage non-small cell lung cancer (NSCLC), treatment strategies have changed significantly due to the introduction of targeted therapies and immunotherapy. In the last few years, we have seen an explosive growth of newly introduced targeted therapies in oncology and this development is expected to continue in the future. Besides primary targetable aberrations, emerging diagnostic biomarkers also include relevant co-occurring mutations and resistance mechanisms involved in disease progression, that have impact on optimal treatment management. Toaccommodate testing of pending biomarkers, it is necessary to establish routine large-panel next-generationsequencing (NGS) for all patients with advanced stage NSCLC. For cost-effectiveness and accessibility, it is recommended to implement predictive molecular testing using large-panel NGS in a dedicated, centralized expert laboratory within a regional oncology network. The central molecular testing center should host a regional Molecular Tumor Board and function as a hub for interpretation of rare and complex testing results and clinical decision-making. Copyright (c) 2024 The Authors. Published by Elsevier Ltd. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).

Language: English

Type (Professor's evaluation): Scientific

No. of pages: 9